SCN CARRIES OUT DIRECTED SHARE ISSUE

(NGM:SCN)

By virtue of shareholder’s meeting’s authorization, the Board of Directors in Scandinavian Clinical Nutrition i Sverige AB (publ) have decided to carry out a directed share issue. The main purpose of the share issue is to secure funding for ongoing R&D and product development within the subsidiary Scandivir AB.

The company’s share capital shall increase by a maximum of SEK 178,000 through a new share issue by a maximum of 1,780,000 shares (each with a quote value of SEK 0.1). Subscribed shares will carry right to dividend that occurs closest after that subscription has taken place. The shares are issued at a subscription price of SEK seven (7). The subscription price is equivalent to the shares market value calculated as the average stock price during 30 trading days before the decision, with deduction for a minor placement discount. Subscription and payment for shares shall be made from December 10 until and including December 23, 2008.

Right to subscription shall, without preferential right of the shareholders, be granted to a limited number of financial investors. The reason for the deviation from the shareholders preferential right is that the Board of Directors estimates that a directed share issue best takes care of the company’s opportunities to promptly and to a market valuation raise sufficient funds to the company during current market prerequisites and conditions in the company.

For more information, please contact:

Thomas Christensen, CEO, tc@scnutrition.com, +47 922 55 444

Ulf Söderberg, Chairman of the Board, us@scnutrition.com, +46 708 13 22 81

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).For more information, please visit www.scnutrition.com.